MeiraGTx (NASDAQ:MGTX) issued its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.22, Fidelity Earnings reports. The business had revenue of $3.58 million for the quarter.
Shares of MGTX opened at $14.46 on Friday. The firm has a market capitalization of $488.19 million, a PE ratio of -3.29 and a beta of 2.05. The company has a debt-to-equity ratio of 0.12, a current ratio of 5.22 and a quick ratio of 5.22. MeiraGTx has a 1-year low of $8.53 and a 1-year high of $30.23. The company’s fifty day moving average price is $15.38 and its 200-day moving average price is $20.90.
A number of brokerages have recently weighed in on MGTX. ValuEngine raised shares of MeiraGTx from a “sell” rating to a “hold” rating in a report on Thursday, October 10th. Chardan Capital reissued a “buy” rating and set a $45.00 price objective on shares of MeiraGTx in a report on Monday, September 23rd. Finally, Piper Jaffray Companies began coverage on shares of MeiraGTx in a report on Tuesday, September 3rd. They set an “overweight” rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $33.75.
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.
See Also: Market Timing
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.